Noticias de stock de antares pharma
Antares Pharma, Inc. focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. Today it was reported that a Director at Antares Pharma (ATRS – Research Report), Leonard Jacob, exercised options to buy Antares Pharma (ATRS): If you are considering getting into the day trading or penny stock market, it’s a legitimate and profitable method for making a living. Every good investor knows that in order to make money on any investment, you… Antares Pharma has generated ($0.04) earnings per share over the last year. Antares Pharma has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 27th, 2020 based off prior year's report dates. Antares Pharma Earnings Estimates and Actuals by Quarter
11/14/2017 · Antares stock had dropped 61% from a recent high after the company received notification from the FDA that it would not approve Xyosted in October. The FDA action did not involve issues involving the chemistry, manufacturing and controls, or the efficacy of the Antares device, but cited potential issues of blood pressure and depression.
Find the latest Antares Pharma, Inc. (ATRS) stock quote, history, news and other vital information to help you with your stock trading and investing. Do Directors Own Antares Pharma, Inc. (NASDAQ:ATRS) Shares? News. Simply Wall St.•3 1 day ago After a big run-up in its share price following better-than-expected earnings and guidance in November, Antares Pharma (NASDAQ:ATRS) ATRS | Complete Antares Pharma Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. Get Antares Pharma Inc (ATRS:NASDAQ) real-time stock quotes, news and financial information from CNBC. Get breaking news and analysis on Antares Pharma, Inc. (ATRS) stock, price quote and chart, trading and investing tools. 11/5/2019 · Find the latest Antares Pharma, Inc. (ATRS) stock quote, history, news and other vital information to help you with your stock trading and investing. ATRS Real Time Stock Quote - Get Antares Pharma, Inc. Common Stock (ATRS) last sale data in real-time at NASDAQ.com.
12/24/2019 · Real time Antares Pharma (ATRS) stock price quote, stock graph, news & analysis.
Antares Pharma Announces Receipt of Final Payment from Sale of Zomajet™ Needle-Free Delivery System. 29 Oct 2019 Antares Pharma to Report Third Quarter 2019 Financial and Operating Results . 24 Oct 2019 Antares Pharma Announces Two Poster Presentations at the 2019 Sexual Medicine Society Scientific Annual Meeting . 17 Sep 2019 12/27/2019 · antares pharma inc (atrs): * antares pharma reports third quarter 2019 operating and financial results. * q3 earnings per share $0.01. * q3 revenue rose 92 percent to $34.3 million. * q3 revenue estimate $26.9 million -- refinitiv ibes data.
3 analysts have issued 12 month price objectives for Antares Pharma's shares. Their forecasts range from $1.99 to $5.65. On average, they anticipate Antares Pharma's stock price to reach $4.05 in the next twelve months. This suggests that the stock has a possible downside of 13.9%. View Analyst Price Targets for Antares Pharma.
10/13/2017 · Why Antares Pharma Inc Plummeted Today An FDA rejection is coming for the drugmaker's testosterone replacement therapy Xyosted. 12/24/2019 · Antares Pharma, Inc. Common Stock (ATRS) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.
11/14/2017 · Antares stock had dropped 61% from a recent high after the company received notification from the FDA that it would not approve Xyosted in October. The FDA action did not involve issues involving the chemistry, manufacturing and controls, or the efficacy of the Antares device, but cited potential issues of blood pressure and depression.
12/24/2019 · Antares Pharma, Inc. Common Stock (ATRS) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Read current news for ATRS. Antares Pharma Announces Two Poster Presentations at the 2019 Sexual Medicine Society Scientific Annual Meeting 12/31/2019 · Get the latest Antares Pharma, Inc. (ATRS) stock news and headlines to help you in your trading and investing decisions. ATRS News: Antares Pharma Social Media Campaign for XYOSTED® Wins MarCom Platinum Award: 12/06/2019 07:00:10 AM: ATRS News: Antares Pharma to Present at the 31st Annual Piper Jaffray Healthcare Conference: 11/27/2019 05:51:22 PM: ATRS News: REMINDER: Antares Pharma Enters Into a Global Development Agreement With Idorsia Pharmaceuticals Ltd.
3 analysts have issued 12 month price objectives for Antares Pharma's shares. Their forecasts range from $1.99 to $5.65. On average, they anticipate Antares Pharma's stock price to reach $4.05 in the next twelve months. This suggests that the stock has a possible downside of 13.9%. View Analyst Price Targets for Antares Pharma. 12/24/2019 · Real time Antares Pharma (ATRS) stock price quote, stock graph, news & analysis. 3/18/2019 · Stock analysis for Antares Pharma Inc (ATRS:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. ATRS | Complete Antares Pharma Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. 11/14/2017 · Antares stock had dropped 61% from a recent high after the company received notification from the FDA that it would not approve Xyosted in October. The FDA action did not involve issues involving the chemistry, manufacturing and controls, or the efficacy of the Antares device, but cited potential issues of blood pressure and depression. Real-time trade and investing ideas on Antares Pharma Inc. ATRS from the largest community of traders and investors. Antares Pharma Appoints Edward Tykot Senior Vice President, Corporate Development Read More. 06 Dec 2019 Antares Pharma Social Media Campaign for XYOSTED® Wins Marcom Platinum Award Read More. 27 Nov 2019 Antares Pharma To Present At The 31st Annual Piper Jaffray Healthcare Conference Read More